Leaflet DARUNAVIR TEVA 800mg film-coated tablets
Indicated for: HIV-1 infection
Route of administration: oral
Substance: darunavir (protease inhibitor)
ATC: J05AE10 (Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the HIV protease enzyme, which is essential for viral replication, thereby reducing the viral load.
The medication is taken orally, usually once daily, in combination with other antiretroviral drugs. Common side effects include nausea, diarrhea, headaches, and skin rashes.
Darunavir is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe hepatic conditions.
This medication is an important option for managing HIV infection, helping to improve patients' quality of life and prevent disease progression.
General data about DARUNAVIR TEVA 800mg
- Substance: darunavir
- Date of latest medicines list: 01-06-2026
- Product code: W64415010
- Concentration: 800mg
- Pharmaceutical form: film-coated tablets
- Quantity: 30
- Product type: Generic medicine
- Price: 1016.48 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for darunavir
Concentrations available for darunavir
- 100mg/ml
- 150mg
- 300mg
- 400mg
- 600mg
- 75mg
- 800mg
Combinations with other substances
Compensation lists for DARUNAVIR TEVA 800mg Teva
NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment
Price
Copayment
Patient
1016.48 RON
1012.22 RON
4.26 RON